TMS and Bipolar Depression: What the Research Shows
If you’re researching TMS for bipolar depression, you deserve a straight answer. Here’s
what the science says, what it doesn’t say yet, and why an accurate diagnosis has to come
before any conversation about treatment.
- ✓ Board-certified psychiatric evaluation
- ✓ Careful screening for unipolar vs. bipolar depression
- ✓ Honest guidance on your options, even when TMS isn’t one
DTIP’s TMS treatment is FDA-cleared for Major Depressive Disorder (MDD) —
specifically, for depressive episodes (and associated anxiety symptoms) in adults who have
not responded well to prior antidepressant treatment. Bipolar depression is not
part of DTIP’s current TMS protocol. The MagVenture TMS system we use has not
been established as safe and effective for patients with bipolar disorder, and treatment
guidelines list psychotic and bipolar conditions as populations where that evidence does
not yet exist for this device.
This page exists to answer your questions honestly, not to offer TMS as a bipolar
depression treatment. If a full evaluation at DTIP suggests bipolar disorder rather than
unipolar (MDD) depression, we won’t move forward with our standard TMS protocol — we’ll
talk with you about what does make sense next.
Why Unipolar vs. Bipolar Depression Matters So Much
Bipolar depression and unipolar (major) depression can look nearly identical in a single
appointment — low mood, fatigue, loss of interest, sleep and appetite changes, difficulty
concentrating. But they are different illnesses, and treating one as if it were the other
carries real risk.
People with bipolar disorder cycle between depressive episodes and periods of mania or
hypomania (elevated mood, high energy, impulsivity, reduced need for sleep). Someone in a
bipolar depressive episode may never mention past hypomanic periods — sometimes because
those episodes felt good and weren’t seen as a problem, sometimes because they were brief,
mild, or years ago. That’s exactly why a thorough psychiatric history, not just a symptom
checklist, is essential before starting any depression treatment.
Antidepressant-type treatments — medications and, potentially, some forms of brain
stimulation — are generally considered in bipolar disorder only alongside mood-stabilizing
coverage, because there is a recognized concern (long documented with antidepressant
medications) about triggering a manic or hypomanic switch when a depressive episode is
treated without that coverage. This is a core reason bipolar disorder is treated as a
distinct clinical pathway, and why it sits outside the FDA clearance for DTIP’s TMS device.
What the Research on TMS and Bipolar Depression Actually Shows
Bipolar depression is difficult to treat, and researchers have been studying whether TMS
could eventually play a role. The literature is real, it’s evolving, and it deserves an
honest summary — separate from what DTIP itself offers today.
Switch risk appears more reassuring than the general concern might suggest
A 2021 systematic review and meta-analysis pooling 25 randomized controlled trials across
mood disorders — including bipolar depression — found that the risk of a hypomanic or
manic switch was not significantly different between active TMS and sham
(placebo) stimulation. This is meaningful, reassuring safety data from the
broader scientific literature.
It is not, however, a statement about DTIP’s own outcomes, an FDA clearance, or an
indication that this evidence changes DTIP’s current protocol.
transcranial magnetic stimulation in mood disorders: A systematic review and
meta-analysis.” World J Psychiatry. 2021;11(8):477–490.
DOI: 10.5498/wjp.v11.i8.477
TMS is not currently FDA-approved for bipolar depression
A 2018 study looked at patients with unipolar MDD who showed subthreshold “soft signs” of
bipolarity — not a full bipolar diagnosis — and how that affected their response to TMS
for depression. In their own words, the authors note plainly: “TMS is not currently
FDA approved for depressed patients with bipolar disorder (BD).”
It’s worth being precise here: this study was about unipolar depression patients with
soft bipolar features, not about treating diagnosed bipolar disorder with TMS. But the
statement of the current FDA landscape is exactly the point — and it matches DTIP’s
position today.
impact outcomes following Transcranial Magnetic Stimulation (TMS) therapy for
depression?” J Affect Disord. 2018;245:237–240.
DOI: 10.1016/j.jad.2018.10.367
Evidence for treating bipolar disorder directly is still mixed
A 2018 clinical review of repetitive TMS (rTMS) for PTSD, generalized anxiety disorder,
and bipolar disorder concluded that “the results for treating either phase of bipolar
disorder are mixed, with most of the current studies showing lack of benefit over sham.
Further study is required before rTMS can be recommended for these disorders.”
Posttraumatic Stress Disorder, Generalized Anxiety Disorder, and Bipolar Disorder.”
Psychiatr Clin North Am. 2018;41(3):433–446.
DOI: 10.1016/j.psc.2018.04.007
Some newer, different equipment shows early promise
A 2017 randomized, sham-controlled trial using Deep TMS with an H1-coil — a different
device and stimulation protocol than the MagVenture system used at DTIP — found some
benefit over sham in a relatively small group of bipolar depression patients. It’s a
meaningful data point for the field, but it reflects different equipment and a different
protocol than what DTIP provides, so it should not be read as a description of DTIP’s own
treatment or results.
Depression with Deep TMS: Results from a Double-Blind, Randomized, Parallel Group,
Sham-Controlled Clinical Trial.” Neuropsychopharmacology. 2017;42(13):2593–2601.
DOI: 10.1038/npp.2017.26
Where the evidence stands today: Much of the research on TMS for bipolar
depression uses different devices and stimulation protocols than DTIP’s MagVenture
system, sample sizes in these trials are generally small, and TMS for bipolar depression
is not an FDA-cleared indication for any TMS device on the market today, including
DTIP’s. This is genuinely an active area of research — not an established treatment path
at DTIP, and not something we offer or promote as a service today.
DTIP’s Approach: Getting the Diagnosis Right First
Because unipolar and bipolar depression can look so similar on the surface, DTIP’s intake
process is built to tell them apart before any treatment decision is made — not after.
Thorough psychiatric evaluation
A full history — including past mood episodes, family history, and prior treatment response — reviewed by a psychiatric provider, not just a symptom questionnaire.
Screening for bipolar features
Specific screening for current or past hypomanic/manic symptoms, since these are often under-reported and change the entire treatment picture.
Honest next steps
If bipolar disorder is suspected or confirmed, we won’t proceed with TMS under our MDD protocol. Instead, we’ll talk through appropriate next steps and referral options with you.
If your evaluation confirms unipolar Major Depressive Disorder and you meet DTIP’s clinical
criteria — including a history of insufficient response to antidepressant medication — TMS
may be an appropriate option to discuss. That determination always follows the evaluation;
it’s never assumed beforehand.
Common Questions
Does DTIP treat bipolar depression with TMS?
No. DTIP’s TMS treatment is FDA-cleared for Major Depressive Disorder (MDD) in adults
who have not responded well to prior antidepressant treatment. Bipolar depression is
not part of our current TMS protocol, and we do not offer, market, or provide TMS as a
bipolar depression treatment.
Why doesn’t DTIP offer TMS for bipolar depression?
The MagVenture TMS system DTIP uses has FDA clearance specifically for MDD. Psychotic
and bipolar conditions are listed as populations where safety and effectiveness with
this device have not been established. Research on TMS for bipolar depression is
ongoing and shows some encouraging signals — but it generally involves different
devices, different protocols, and small study sizes, and it has not reached the point
of FDA clearance for any TMS system, including ours.
What if I’m not sure whether I have bipolar or unipolar depression?
That uncertainty is common, and it’s exactly what a proper evaluation is for. Many
people with bipolar disorder are initially diagnosed with unipolar depression because
past hypomanic or manic periods were brief, mild, or never reported. DTIP’s evaluation
process is designed to look carefully for those signs before any treatment
recommendation is made.
What should I do instead if bipolar disorder is suspected?
Start with a comprehensive psychiatric evaluation, whether that’s with DTIP or another
qualified provider. Bipolar disorder is typically managed with mood-stabilizing
treatment under a psychiatrist’s care. If DTIP’s evaluation points to bipolar disorder
rather than MDD, we’ll discuss appropriate next steps and referral options with you
directly — we won’t leave you without a direction forward.
Is it safe to ask DTIP about this even if TMS isn’t an option for me?
Yes. A conversation with a provider about your diagnosis and options doesn’t commit you
to any treatment. We’d rather give you an accurate picture — including telling you when
something isn’t the right fit — than let you guess.
Talk to a Provider About Your Diagnosis and Options
Whether you’re dealing with treatment-resistant unipolar depression or you’re trying to
understand whether bipolar disorder might be part of the picture, a real evaluation is
the right next step — not a guess based on a symptom list. Reach out and we’ll help you
understand where you stand.
This page is for general educational purposes and reflects published scientific literature
as of the date of writing. It is not medical advice and does not describe a treatment DTIP
currently offers for bipolar depression. TMS outcomes vary by individual, and no specific
result is guaranteed. Only a licensed provider can determine whether TMS or any other
treatment is appropriate for you, and only after a full evaluation.
If you are in crisis, call or text 988.